Challenges and Gaps in Clinical Trial Genomic Data Management.
作者信息
Asad Sarah, Kananen Kathryn, Mueller Kurt R, Symmans W Fraser, Wen Yujia, Perou Charles M, Blachly James S, Chen James, Vincent Benjamin G, Stover Daniel G
机构信息
Ohio State University Comprehensive Cancer Center, Columbus, OH.
University of Texas MD Anderson Cancer Center, Houston, TX.
出版信息
JCO Clin Cancer Inform. 2022 Mar;6(1):e2100193. doi: 10.1200/CCI.21.00193.
Abstract
摘要
相似文献
1
Challenges and Gaps in Clinical Trial Genomic Data Management.临床试验基因组数据管理中的挑战与差距
JCO Clin Cancer Inform. 2022 Mar;6(1):e2100193. doi: 10.1200/CCI.21.00193.
2
Commentary on ICH guideline on genomic sampling and data management-enabling opportunities in drug development and patient treatment.关于 ICH 基因组采样和数据管理指南的评论——在药物开发和患者治疗中创造机会。
Br J Clin Pharmacol. 2020 Aug;86(8):1454-1464. doi: 10.1111/bcp.14305. Epub 2020 May 18.
3
Ontology based data management systems for post-genomic clinical trials within a European Grid Infrastructure for Cancer Research.欧洲癌症研究网格基础设施内基于本体的数据管理系统用于基因组学后临床试验。
Annu Int Conf IEEE Eng Med Biol Soc. 2007;2007:6435-8. doi: 10.1109/IEMBS.2007.4353829.
4
Successes and lessons learned in database development for national multi-site cancer care delivery research trials: the Alliance for Clinical Trials in Oncology experience.在国家多站点癌症护理提供研究试验的数据库开发方面取得的成功和经验教训：肿瘤临床研究联盟的经验。
Trials. 2022 Aug 9;23(1):645. doi: 10.1186/s13063-022-06536-x.
5
Clinical Trials in the Genomic Era.基因组时代的临床试验
J Clin Oncol. 2017 Mar 20;35(9):1011-1017. doi: 10.1200/JCO.2016.70.8891. Epub 2017 Feb 13.
6
Management and return of incidental genomic findings in clinical trials.临床试验中偶然基因组发现的管理与反馈
Pharmacogenomics J. 2015 Feb;15(1):1-5. doi: 10.1038/tpj.2014.62. Epub 2014 Oct 28.
7
Genomics-based early-phase clinical trials in oncology: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.肿瘤学中基于基因组学的早期临床试验：创新癌症治疗方法开发方法特别工作组的建议
Eur J Cancer. 2014 Nov;50(16):2747-51. doi: 10.1016/j.ejca.2014.07.027. Epub 2014 Sep 15.
8
Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons.在不中断火车运行的情况下更换平台：通过添加和关闭比较来适应平台协议时的数据管理和数据管理系统的经验。
Trials. 2019 May 29;20(1):294. doi: 10.1186/s13063-019-3322-7.
9
Randomized controlled trial on the effectiveness of web-based Genomics Nursing Education Intervention for undergraduate nursing students: a study protocol.基于网络的基因组学护理教育干预对本科护生效果的随机对照试验：研究方案。
J Adv Nurs. 2020 Nov;76(11):3136-3146. doi: 10.1111/jan.14477. Epub 2020 Aug 25.
10
Genomic Alteration-Driven Clinical Trial Designs in Oncology.肿瘤学中基于基因组改变的临床试验设计。
Ann Intern Med. 2016 Aug 16;165(4):270-8. doi: 10.7326/M15-2413. Epub 2016 May 24.
引用本文的文献
1
Genetics and precision genomics approaches to pulmonary hypertension.遗传学和精准基因组学在肺动脉高压中的应用。
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01370-2024. Print 2024 Oct.
本文引用的文献
1
Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.三阴性乳腺癌新辅助化疗病理完全缓解与免疫表型的相关性：BrighTNess Ⅲ期随机临床试验的二次分析。
JAMA Oncol. 2021 Apr 1;7(4):603-608. doi: 10.1001/jamaoncol.2020.7310.
2
Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.三阴性乳腺癌中的同源重组缺陷和宿主抗肿瘤免疫。
Breast Cancer Res Treat. 2018 Aug;171(1):21-31. doi: 10.1007/s10549-018-4807-x. Epub 2018 May 7.
3
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.在三阴性乳腺癌（BrighTNess）中，将 PARP 抑制剂 veliparib 联合卡铂或卡铂单药添加到标准新辅助化疗中：一项随机、3 期试验。
Lancet Oncol. 2018 Apr;19(4):497-509. doi: 10.1016/S1470-2045(18)30111-6. Epub 2018 Feb 28.
4
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.维利帕尼-卡铂治疗乳腺癌的适应性随机分组
N Engl J Med. 2016 Jul 7;375(1):23-34. doi: 10.1056/NEJMoa1513749.
5
The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis.增殖在确定乳腺癌新辅助化疗反应中的作用：基于基因表达的荟萃分析。
Clin Cancer Res. 2016 Dec 15;22(24):6039-6050. doi: 10.1158/1078-0432.CCR-16-0471. Epub 2016 Jun 21.
6
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.三阴性乳腺癌分子亚型的细化：对新辅助化疗选择的影响
PLoS One. 2016 Jun 16;11(6):e0157368. doi: 10.1371/journal.pone.0157368. eCollection 2016.
7
Data Sharing.数据共享。
N Engl J Med. 2016 Jan 21;374(3):276-7. doi: 10.1056/NEJMe1516564.
8
Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer.为三阴性乳腺癌患者量身定制辅助化疗方案。
Breast. 2015 Nov;24 Suppl 2:S132-5. doi: 10.1016/j.breast.2015.07.032. Epub 2015 Aug 5.
9
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.吉西他滨、卡铂和依尼帕利作为三阴性及BRCA1/2突变相关乳腺癌新辅助治疗的II期研究，并评估基于肿瘤的基因组不稳定性指标：PrECOG 0105。
J Clin Oncol. 2015 Jun 10;33(17):1895-901. doi: 10.1200/JCO.2014.57.0085. Epub 2015 Apr 6.
10
Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.全面基因组分析确定三阴性乳腺癌的新亚型和靶点。
Clin Cancer Res. 2015 Apr 1;21(7):1688-98. doi: 10.1158/1078-0432.CCR-14-0432. Epub 2014 Sep 10.
Zotero 插件